[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349892-105":59,"doc-detail-349892-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","real-world-clinical-utility-of-comprehensive-genomic-profiling-in-advanced-solid-tumors","Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors","","Comprehensive genomic profiling (CGP) supports precision oncology, yet real-world effectiveness has been uncertain. A nationwide Japanese database analysis included 54,185 patients with advanced solid tumors across 81 tumor types receiving CGP with a 324-gene panel. CGP-guided evidence-level classification identified response-predicting alterations in 16.6% and 8.1% of patients, linked to better prognosis. Only 8% received approved–experimental biomarker-linked therapies, varying sharply by tumor type. Tumor-agnostic results showed TMB ≥20 mutations per megabase predicts improved outcomes with pembrolizumab, while extramammary Paget’s disease remained highly resistant.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-clinical-utility-of-comprehensive-genomic-profiling-in-advanced-solid-tumors/349892/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-clinical-utility-of-comprehensive-genomic-profiling-in-advanced-solid-tumors/349892.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What dataset and assay were used to evaluate CGP in advanced solid tumors?","Question",{"text":113,"@type":114},"The study analyzed data from the Japanese nationwide Center for Cancer Genomics and Advanced Therapeutics database, using a targeted sequencing panel covering 324 genes for 54,185 patients across 81 tumor types.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How often did CGP-guided alterations predict response to approved therapies?",{"text":118,"@type":114},"Alterations predicting response to therapies approved by relevant agencies were detected in 16.6% of patients, while those supported by well-powered studies with expert consensus were detected in 8.1%.",{"name":120,"@type":111,"acceptedAnswer":121},"Which tumor-agnostic biomarker showed predictive value across tumor types?",{"text":122,"@type":114},"Tumor mutational burden (TMB) ≥20 mutations per megabase predicted better outcomes across tumor types in TMB-high patients receiving pembrolizumab, regardless of microsatellite instability status.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},349892,1790830928,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","nature medicine  \nArticle [https://doi.org/10.1038/s41591-025-04086-8](https://doi.org/10.1038/s41591-025-04086-8)  \nReal-world clinical utility of comprehensive genomic profiling in advanced solid tumors  \nReceived: 19 May 2025  \nAccepted: 29 October 2025  \n\n| Published online: 6 January 2026 |\n| --- |\n|  Check for updates |\n\nA list of authors and their affiliations appears atthe end of the paper  \nComprehensive genomic profiling (CGP) is crucial in precision oncology, yet its real-world utility remains unclear. Here we analyzed data from the Japanese nationwide Center for Cancer Genomicsand Advanced Therapeutics database, including clinical and genetic data from 54,185 patients with advanced solid tumors (consisting of 81 common and  \nrare tumor types) who received CGPwitha targeted sequencing panel covering 324 genes as part of their clinical care. We assessed the prognostic value ofCGP-guided clinical evidence-level classification, showing that alterations predicting response to Pharmaceuticals and Medical Devices Agency-approved or Food and Drug Administration-approved therapies and to therapies supported by well-powered studies with expert consensus are detected in 16.6% and 8.1% of patients, respectively, and are associated with better prognosis than those with lower clinical evidence levels. Only 8% of patients receive CGP-guided approved–experimental genomic biomarker-linked therapies, although the proportion has improved overtime. Substantial differences were observed across tumor types, with the proportions exceeding 20% in thyroid and lung cancers but remaining below 2% in pancreatic and liver cancers. Tumor-agnostic biomarker analyses reveal that tumor mutational burden (TMB) ≥20 mutations per megabase predicts better outcome across tumor types, regardless of microsatellite instability status, inTMB-high patients receiving pembrolizumab. Conversely, extramammary Paget ʼs disease is exceptionally resistant topembrolizumab. The large-scale nationwide database allows evaluating inter-tumor type differences and investigating evidence-scarce situations, delineating where CGP offers greater benefit. These real-world findings complement those from clinical trials and prospective sequencing projects regarding CGP, providing valuable information for individualized treatment.  \nLarge-scale clinicogenomic studies using next-generation sequencing (NGS) have revealed the clinical utility of driver alterations as diagnostic and prognostic biomarkers and have facilitated the development of molecularly targeted therapies or genomic biomarker-linked therapies. Although a few genomic biomarker-linked therapies, including erlotinib forEGFR-mutated non-small cell lung cancer (NSCLC), existed in the pre-NGS era, their development has substantially expanded thereafter1,2. These therapies include not only tumor-type-specific but  \nalso tumor-agnostic therapies, such as entrectiniband larotrectinib for NTRK fusionsand pembrolizumab for high TMB (TMB-H). The availability of genomic biomarker-linked therapies differs among tumor types: clinically actionable alterations are frequent in lung, breast and thyroid cancers but rare in pancreatic and cervical cancers1–4.  \nCompanion diagnostic (CDx) assays are critical for selecting appropriate patients for molecularly targeted therapies. Traditionally, immunohistochemistry (IHC) and individual gene testing, such as  \ne-mail: [kkataoka-tky@umin.ac.jp](kkataoka-tky@umin.ac.jp)  \nin situ hybridization (ISH) and polymerase chain reaction (PCR), have been utilized. Recently, with the development of numerous genomic biomarker-linked therapies, the identification of many actionable alterations has become necessary. Thus, NGS-based CGP has been increasingly performed to simultaneously evaluate somatic alterationsin hundreds of cancer-related genes1,5. In addition, several CGPassays were approved as CDx for tumor-agnostic indications6,7, including FoundationOne CDx (F1CDx), a targeted sequencing panel co","cbCaiob0DEqJX2SC","https://ap.wps.com/l/cbCaiob0DEqJX2SC","pdf",2281585,31,"English","# Real-world clinical utility of CGP\n## Evidence-level classification and prognosis\n## Tumor-type variation in actionable findings\n## Tumor-agnostic biomarker analyses\n## Companion diagnostics and CGP workflow","[{\"question\":\"What dataset and assay were used to evaluate CGP in advanced solid tumors?\",\"answer\":\"The study analyzed data from the Japanese nationwide Center for Cancer Genomics and Advanced Therapeutics database, using a targeted sequencing panel covering 324 genes for 54,185 patients across 81 tumor types.\"},{\"question\":\"How often did CGP-guided alterations predict response to approved therapies?\",\"answer\":\"Alterations predicting response to therapies approved by relevant agencies were detected in 16.6% of patients, while those supported by well-powered studies with expert consensus were detected in 8.1%.\"},{\"question\":\"Which tumor-agnostic biomarker showed predictive value across tumor types?\",\"answer\":\"Tumor mutational burden (TMB) ≥20 mutations per megabase predicted better outcomes across tumor types in TMB-high patients receiving pembrolizumab, regardless of microsatellite instability status.\"}]","Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors | PDF",1790086089,78,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/62234823199b3e0fc8e92cc668693eae.webp",983,1305,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f8576872bc03e1aff919fd26ecbdd1be.webp",982,1304,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a9a9e3a3291ba57474d6a1c897cdf31b.webp",981,1303,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc7b85da634f9ffe9fdd0f51c8dca5bc.webp",980,1301]